Table of Content


COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 7
Charts 8
Pfizer Inc. - Key Company Facts 9
Pfizer Inc. - Company Description 10
Pfizer Inc. - Top Executives 11
Pfizer Inc.- Top Executives Biographies 12
Pfizer Inc.- Head Office & Locations 16
Head Office - Country 16
Key Subsidiaries 17
Key Joint Ventures 19
Pfizer Inc. - Products and Services 20
Products 20
Services 21
Pfizer Inc. - Historic Events 22
Pfizer Inc. - Company’s Management Discussion 29
Pfizer Inc. - Company’s Mission and Vision 32
Mission 32
Vision 32
Pfizer Inc. - Corporate Strategy 33
Pfizer Inc. - Business Description 37
Biopharma Segment 38
Other Business Activities 38
Pfizer Inc. - ESG Spotlight 39
Environment 40
Social 40
Corporate Governance 41
Pfizer Inc. - SWOT Analysis 42
Overview 42
Strengths 44
Weaknesses 46
Opportunities 47
Threats 50
Pfizer Inc. - PESTLE Analysis 52
Overview 52
Political Factors 54
Economic Factors 55
Social Factors 57
Technological Factors 59
Legal Factors 61
Environmental Factors 62
Pfizer Inc. - Financial Deep Dive 63
Share Price Trend - Oct-2023to Oct-2024 (Average Share Closing Price) 63
Profit and Loss Statement 65
Summary of Profit and Loss Statement 65
Balance Sheet 67
Summary of Balance Sheet 67
Cash Flow Statement 69
Summary of Cash Flow Statement 69
Key Financial Ratio Analysis 71
Pfizer Inc. - Ratio Charts 72
Activity Ratio Charts 72
Growth Ratios Charts 73
Leverage Ratio Charts 74
Liquidity Ratio Charts 74
Profitability Ratio Charts 76
Competing Players 77
Snapshot of Competing Players 78
AbbVie Inc 78
Key Company Facts 78
Company Description 78
Snapshot of Competing Players 80
GSK plc 80
Key Company Facts 80
Company Description 80
Snapshot of Competing Players 82
Johnson & Johnson 82
Key Company Facts 82
Company Description 82
Snapshot of Competing Players 84
Novartis AG 84
Key Company Facts 84
Company Description 84
Snapshot of Competing Players 86
Sanofi SA 86
Key Company Facts 86
Company Description 86
Pfizer Inc. - In the News 88
25-Sep-2024- Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA (voxelotor) From Worldwide Markets 88
20-Sep-2024- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union 89
17-Sep-2024- Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts 92
14-Sep-2024- Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia 93
14-Sep-2024- Pfizer’s BRAFTOVI + MEKTOVI Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer 95
11-Sep-2024- Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024 98
21-Jul-2023- Pfizer announces post-Tornado relief plans for Rocky Mount Community and manufacturing facility 100
19-Jul-2023- Pfizer announces New England Journal of Medicine publication on Group B Streptococcus (GBS) maternal vaccine candidate 100
28-Jun-2023- FDA approves Pfizer’s NGENLA?, a long-acting once-weekly treatment for pediatric growth hormone deficiency 100
27-Jun-2023- FDA accepts Pfizer’s application for Hemophilia B gene therapy Fidanacogene Elaparvovec 101
26-Jun-2023- Pfizer provides update on GLP-1-RA clinical development program for adults with Obesity and Type 2 Diabetes Mellitus 101
23-Jun-2023- FDA approves Pfizer’s LITFULO? (Ritlecitinib) for adults and adolescents with severe alopecia areata 101
20-Jun-2023- Pfizer’s TALZENNA? in combination with XTANDI? receives U.S. FDA approval 101
01-Jun-2023- Phase 3 studies of Pfizer’s novel antibiotic combination offer new treatment hope for patients with multidrug-resistant infections and limited treatment options 101

31-May-2023- U.S. FDA approves ABRYSVO?, Pfizer’s vaccine for the prevention of Respiratory Syncytial Virus (RSV) in older adults 102

30-May-2023- Pfizer announces positive Marstacimab results from pivotal phase 3 Hemophilia A and B trial 102
Pfizer Inc.- Key Deals 103
18-Jul-2023 - Flagship Pioneering and Pfizer partner to accelerate development of innovative medicines targeting unmet needs 103
13-Mar-2023 - Pfizer invests $43 Billion to battle cancer 103
06-Jan-2023 - Longevity Biotech Gero entered a research collaboration with Pfizer to discover potential targets for fibrotic diseases 103
01-Dec-2022 - Roivant and Pfizer form new Vant company focused on developing TL1A drug candidate for inflammatory and fibrotic diseases 103
10-Nov-2022 - Fox Chase Cancer Center and Sylvester Comprehensive Cancer Center collaborate with Pfizer’s Institute of Translational Equitable Medicine to identify novel genetic drivers of Cancer Disparities in African Ancestry Populations 104
04-Oct-2022 - Voyager Therapeutics announces Pfizer license of next-generation AAV Capsid for rare neurologic disease target 104
20-Sep-2022 - CytoReason announces expanded collaboration deal with Pfizer to deliver AI for drug discovery and development 104
08-Aug-2022 - Pfizer to acquire Global Blood Therapeutics for $5.4 Billion to enhance presence in rare hematology 104
21-Jun-2022 - Truveta announces strategic collaboration with Pfizer to accelerate safety insights in real time 104
20-May-2022 - NetVation DL Medicine announces research collaboration with Pfizer Inc. 105
10-May-2022 - Pfizer to acquire Biohaven Pharmaceuticals 105
Appendix 106
Definitions 106
SWOT Analysis 106
PESTLE Analysis 106
Value Chain Analysis 106
ESG Spotlight 106
Financial Deep Dive 106
Financial Ratios - 107
Activity Ratios 107
Growth Ratios 108
Leverage Ratios 109
Liquidity Ratios 110
Market Ratios 111
Profitability Ratios 111
Research Methodology 112
Disclaimer 113
Contact Us 113



List of Figures

Charts
Figure 1: Pfizer Inc.- SWOT Analysis 43
Figure 2: Pfizer Inc. - PESTLE Analysis 53
Figure 3: Pfizer Inc. - Average Share Price Trend - Oct-2023 to Oct-2024 64
Figure 4: Pfizer Inc. - Profit and Loss Statement - 2020-2023 66
Figure 5: Pfizer Inc. - Balance Sheet - 2020-2023 68
Figure 6: Pfizer Inc. - Cash Flow Statement 2020-2023 70
Figure 7: Pfizer Inc. - Activity Ratio Charts 72
Figure 8: Pfizer Inc. - Growth Ratio Charts (Value %) 73
Figure 9: Pfizer Inc. - Leverage Ratio Charts 74
Figure 10: Pfizer Inc. - Liquidity Ratio Charts 75
Figure 11: Pfizer Inc. - Profitability Ratio Charts (Value %) 76
Figure 12: Competing Players - AbbVie Inc - Key Financials 79
Figure 13: Competing Players - GSK plc - Key Financials 81
Figure 14: Competing Players - Johnson & Johnson - Key Financials 83
Figure 15: Competing Players - Novartis AG - Key Financials 85
Figure 16: Competing Players - Sanofi SA - Key Financials 87

List of Tables

Tables
Table 1: Pfizer Inc. - Company Facts
Table 2: Pfizer Inc. - Top Executives
Table 3: Pfizer Inc. - Top Executives Biographies
Table 4: Pfizer Inc. - Subsidiaries
Table 5: Pfizer Inc. - Key Joint Ventures
Table 6: Pfizer Inc. - Products
Table 7: Pfizer Inc. - Services
Table 8: Pfizer Inc. - Historic Events
Table 9: Pfizer Inc. - Share Price Trend - Oct-2023 to Oct-2024
Table 10: Pfizer Inc.- Ratio Analysis - 2020-2023
Table 11: Pfizer Inc. -Competing Players